Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 22 August 1997:
Vol. 277. no. 5329, pp. 1028 - 1030
DOI: 10.1126/science.277.5329.1028
Prev | Table of Contents | Next

News

SCIENTIFIC COMMUNITY:
A Bitter Battle Over Insulin Gene

Eliot Marshall

When the University of California sued Eli Lilly and Company to uphold its patent rights on the insulin gene, little did it expect to come away empty-handed, with $12 million in legal bills and its researchers accused of "inequitable conduct." That's what happened 18 months ago, when a federal court ruled in Lilly's favor. Last month, an appeals court set aside the inequitable conduct ruling, but let stand the finding that Lilly did not infringe UC's patents.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)